TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00391027
Drug: Inhaled Human Insulin (Exubera®)
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
Study: NCT00577824
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
Study: NCT01493973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02954393
Drug: Placebos active phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
Study: NCT02954393
Drug: Placebos healing phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
Study: NCT02712528
Drug: remifentanil-based
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712528
Drug: sevoflurane-sufentanil balanced
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01890837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
Study: NCT01480310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: may receive up to 3 subcutaneous doses of placebo
Study: NCT03529019
Drug: Ensure Surgery Immunonutrition Shake
Normalized name: Ensure Surgery Immunonutrition Shake (Vanilla)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
Study: NCT00752687
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
Study: NCT03327116
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral, 15 mg per week, 24 weeks
Study: NCT01744353
Drug: Dose level 2/MTD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
Study: NCT03800433
Drug: Trental 400 MG Extended Release Oral Tablet
Normalized name: Trental 400 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablets
Study: NCT03779815
Drug: [18F]Florbetaben
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Drug: \[18F\]Florbetaben~* \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~* Other name: Neuraceq~* Amount: 300 MBq ± 20% bolus, 10mL intravenously
Study: NCT00200668
Drug: FDG = fluorodeoxyglucose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00902707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compare to active Mucinex
Study: NCT03795220
Drug: Lutinus + transfer day 6
Normalized name: LUPINUS ELEGANS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
Study: NCT03795220
Drug: Lutinus + transfer day 7
Normalized name: LUPINUS ELEGANS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
Study: NCT03795220
Drug: No Lutinus + transfer day 6
Normalized name: Yellow No. 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
Study: NCT03795220
Drug: No Lutinus + transfer day 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four parallel groups of patients undergoing fertility treatment (modified natural cycle frozen embryo transfer) will be compared using/not using vaginal progesterone (Lutinus) and subject to blastocyst warming and transfer 6/7 days after hCG trigger.
Study: NCT01521663
Drug: IPX159
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03879447
Drug: Herbal medicine
Normalized name: Herbal medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.
Study: NCT00796003
Drug: JNJ-30979754 20 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
Study: NCT01521663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00548145
Drug: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: duration: 12 months
Study: NCT00882960
Drug: intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
Study: NCT00882960
Drug: intra-nasal fentanyl
Normalized name: fentanyl Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
Study: NCT04254601
Drug: topical erythromycin cream 2% (Akne-Mycin- Egypt)
Approvals — FDA: no, EMA: no, PMDA: no
Description: two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves
Study: NCT02119663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg matching placebo tablets to be administered by mouth twice daily (BID)
Study: NCT01560143
Drug: Tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg IV as a single infusion over 30 minutes
Study: NCT01268566
Drug: MEDI-575
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI-575 as an IV infusion.
Study: NCT00928200
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2/day IV over 15 minutes on day 1
Study: NCT00928200
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
Study: NCT00511121
Drug: STI571 and PEG INTRON
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00864344
Drug: Zoloft® 100 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Pfizer formulated products under fasting conditions
Study: NCT04411706
Drug: Sintilimab Combined With Apatinib and Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
Study: NCT02119663
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
Study: NCT01324362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing
Study: NCT01324362
Drug: FSC 100/50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing
Study: NCT01324362
Drug: FSC 250/50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing
Study: NCT01324362
Drug: FSC500/50mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dosing
Study: NCT00177255
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22.
Study: NCT00352430
Drug: Nitric Oxide/INP Pulse Delivery
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00352430
Drug: Nitric Oxide/INO Pulse Delivery
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01581541
Drug: PU-H71
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
Study: NCT00928200
Drug: Triple Intrathecal Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
Study: NCT03508167
Drug: Dorilax®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets.
Study: NCT03508167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets.
Study: NCT03162419
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
Study: NCT03193710
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil will be used for analgesia in both groups.
Study: NCT02237755
Drug: Gonadotropins
Normalized name: GONADOTROPINS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
Study: NCT01834352
Drug: Walnut Protein Flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
Study: NCT02240355
Drug: RO6885247
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT02240355
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT04239339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for approximately 3 weeks.
Study: NCT01605253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
Study: NCT01210989
Drug: Phyllanthus urinaria
Normalized name: Phyllanthus niruri top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
Study: NCT01210989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
Study: NCT03537950
Drug: PLC
Normalized name: Drive Cane Tip Rplc 3/4 Blk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of PLC.
Study: NCT01764048
Drug: medications following demand protocol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Please see arm description
Study: NCT04573608
Drug: Papacarie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
Study: NCT04573608
Drug: Atraumatic Restorative Treatment
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
Study: NCT00106522
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25mg weekly
Study: NCT00106522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv every 4 weeks
Study: NCT04561752
Drug: ZN-c5
Normalized name: dipentaerythrityl hexa C5-10 acid esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZN-c5 is the study drug.
Study: NCT02908620
Drug: One spray CTY-5339-CB
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
Study: NCT02742766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
Study: NCT00279266
Drug: Thiamine
Normalized name: Thiamine
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01906346
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cocaine will be made available for self-administration during experimental sessions.
Study: NCT02808013
Drug: NDS-446
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02808013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01077245
Drug: Placebo Fine Granules (without CBM588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Fine Granules (without CBM588)
Study: NCT01007149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in vials with solution for subcutaneous injection.
Study: NCT00618813
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00618813
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01521585
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral once daily tablet
Study: NCT01521585
Drug: SEN0014196
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral once daily tablet
Study: NCT02785978
Drug: Levodopa acute challenge
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring
Study: NCT03705819
Drug: [11C]-NOP46
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a microdose (≤10 µg) of \[11C\]-NOP46.
Study: NCT01913340
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo: NS IV x 5 doses
Study: NCT01031979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01706588
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
Study: NCT01332253
Drug: Intravenous ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
Study: NCT04566601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT00362752
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 400 mg po bid
Study: NCT02942056
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03568162
Drug: ISB 830 - Part 1 Group 1
Normalized name: meningococcal group B vaccine 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (SC) every 2 weeks
Study: NCT03568162
Drug: ISB 830 - Part 1 Group 2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (SC) every 2 weeks
Study: NCT03568162
Drug: ISB 830 - Part 1 Group 3
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (SC) every 2 weeks
Study: NCT03568162
Drug: ISB 830 - Part 2 Group 5
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (SC) every 2 weeks
Study: NCT03568162
Drug: Placebo - Part 2 Group 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (SC) every 2 weeks
Study: NCT01115673
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen Caplet - single dose
Study: NCT01115673
Drug: Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Caplet - single dose
Study: NCT05257291
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Supplementation with 1 mg/day of melatonin for 1 year
Study: NCT02227667
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
Study: NCT01593592
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin 500mg b.i.d for 2 weeks
Study: NCT00389493
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be identical in appearance to those of risperidone.
Study: NCT03319823
Drug: Thiazide Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure \<160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment
Study: NCT03319823
Drug: Intensified Thiazide Treatment Group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure \>120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure \>120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is \<120.